ENDRA Life Sciences Q3 net loss narrows on digital asset gains
Overview
US thermoacoustic imaging firm's Q3 net loss narrowed yr/yr, aided by digital asset gains
Company's operating expenses rose due to higher merger-related professional fees
ENDRA focused on completing proposed merger with Noble Africa and $50 mln private placement
Outlook
Company remains focused on completing proposed merger with Noble Africa and related transactions
Completion of the merger is subject to customary closing conditions, including stockholder approvals
Company did not provide specific financial guidance for future quarters or the full year
Result Drivers
MERGER-RELATED COSTS - Higher professional fees and costs tied to the proposed merger with Noble Africa increased operating expenses
DIGITAL ASSET GAINS - Net loss narrowed yr/yr due to realized and unrealized gains on digital assets
REDUCED R&D SPENDING - Research and development expenses declined compared to the prior-year period
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | $1.50 mln | ||
Q3 Operating Expenses | $1.70 mln |
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ENDRA Life Sciences Inc is $25.00, about 466.9% above its November 13 closing price of $4.41
Reuters Recommended Reads
Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall
Nov 16 - Prelude Therapeutics Q3 net loss narrows as expenses fall
Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)